Index -
P/E -
EPS (ttm) -0.28
Insider Own 10.84%
Shs Outstand 194.58M
Perf Week 4.10%
Market Cap 292.38M
Forward P/E -
EPS next Y -0.30
Insider Trans -0.89%
Shs Float 186.87M
Perf Month -7.62%
Income -51.27M
PEG -
EPS next Q -0.07
Inst Own 18.78%
Short Float 7.33%
Perf Quarter -15.45%
Sales 194.75M
P/S 1.50
EPS this Y -0.87%
Inst Trans -8.80%
Short Ratio 2.78
Perf Half Y 58.16%
Book/sh -0.16
P/B -
EPS next Y -7.54%
ROA -17.15%
Short Interest 13.69M
Perf Year 58.54%
Cash/sh 0.20
P/C 6.81
EPS next 5Y -
ROE -554.87%
52W Range 0.78 - 2.48
Perf YTD 12.50%
Dividend Est. -
P/FCF -
EPS past 5Y 35.46%
ROI -103.44%
52W High -43.75%
Beta 0.83
Dividend TTM -
Quick Ratio 1.03
Sales past 5Y 5.16%
Gross Margin 61.47%
52W Low 78.82%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 1.18
EPS Y/Y TTM 47.06%
Oper. Margin -23.32%
RSI (14) 46.79
Volatility 5.91% 5.96%
Employees 167
Debt/Eq -
Sales Y/Y TTM -33.42%
Profit Margin -26.32%
Recom 1.00
Target Price 5.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 106.39%
Payout -
Rel Volume 0.69
Prev Close 1.30
Sales Surprise 1.45%
EPS Surprise 100.00%
Sales Q/Q 2.06%
Earnings May 09 BMO
Avg Volume 4.92M
Price 1.39
SMA20 -0.11%
SMA50 -10.57%
SMA200 5.22%
Trades
Volume 2,360,700
Change 7.31%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Resumed
BTIG Research
Buy
$4
Aug-28-23 Upgrade
H.C. Wainwright
Neutral → Buy
$3.75
May-31-23 Upgrade
Piper Sandler
Neutral → Overweight
$2 → $4
Mar-31-22 Downgrade
Piper Sandler
Overweight → Neutral
$8 → $2
Mar-31-22 Downgrade
Needham
Buy → Hold
Mar-31-22 Downgrade
Mizuho
Buy → Neutral
$6 → $2
Mar-31-22 Downgrade
H.C. Wainwright
Buy → Neutral
$10 → $2
Mar-08-21 Initiated
Cantor Fitzgerald
Overweight
$8
Jan-29-21 Downgrade
JP Morgan
Neutral → Underweight
Nov-14-19 Reiterated
Needham
Buy
$18 → $15
Aug-06-19 Reiterated
H.C. Wainwright
Buy
$19 → $17
Jul-11-19 Reiterated
H.C. Wainwright
Buy
$23 → $21
May-02-19 Initiated
JP Morgan
Overweight
$12
Mar-20-19 Initiated
Citigroup
Neutral
$9
Sep-07-18 Resumed
Morgan Stanley
Equal-Weight
Aug-10-18 Reiterated
Needham
Buy
$20 → $18
Jun-06-18 Reiterated
H.C. Wainwright
Buy
$24 → $22
Dec-19-17 Initiated
Piper Jaffray
Overweight
$26
Dec-07-17 Initiated
BTIG Research
Buy
$30
Sep-15-17 Initiated
RBC Capital Mkts
Sector Perform
$17
Show Previous Ratings
May-02-24 08:30AM
May-01-24 04:05PM
Apr-02-24 04:05PM
Mar-28-24 11:50AM
07:06AM
08:26PM
Loading…
Mar-27-24 08:26PM
Mar-26-24 01:12PM
Mar-14-24 09:53PM
05:51PM
05:30PM
04:15PM
Mar-11-24 05:05PM
Mar-01-24 04:05PM
Feb-02-24 04:05PM
Jan-30-24 08:00AM
08:30AM
Loading…
Jan-09-24 08:30AM
Jan-02-24 04:30PM
Dec-20-23 08:00AM
Dec-01-23 04:05PM
10:00AM
Nov-20-23 08:00AM
Nov-09-23 11:32AM
Nov-08-23 10:05PM
(Thomson Reuters StreetEvents) -11.93%
07:40AM
(Associated Press Finance)
07:30AM
Nov-02-23 04:30PM
Nov-01-23 04:05PM
Oct-31-23 08:00AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
08:00AM
Loading…
Oct-18-23 08:00AM
Oct-03-23 04:05PM
Sep-28-23 08:00AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Sep-05-23 04:05PM
Aug-31-23 06:15AM
(American City Business Journals)
Aug-28-23 12:18PM
11:44AM
08:12AM
Aug-25-23 10:25PM
(Thomson Reuters StreetEvents) -8.00%
09:40AM
08:28AM
08:09AM
Aug-24-23 08:00AM
Aug-23-23 04:35PM
Aug-17-23 04:05PM
Aug-10-23 05:40PM
Aug-01-23 04:30PM
Jul-26-23 09:40AM
Jul-19-23 07:45AM
Jul-18-23 07:45AM
Jul-06-23 06:07AM
Jul-04-23 07:34AM
Jun-29-23 08:00AM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-20-23 08:00AM
Jun-19-23 09:40AM
Jun-13-23 07:00AM
Jun-08-23 01:20PM
09:19AM
Jun-02-23 12:00PM
09:40AM
08:30AM
Jun-01-23 04:05PM
May-30-23 07:30AM
May-25-23 08:00AM
May-23-23 11:27AM
May-22-23 05:15PM
08:30AM
May-10-23 09:40AM
May-09-23 02:12AM
(Thomson Reuters StreetEvents)
May-08-23 08:45AM
07:30AM
May-04-23 10:00AM
May-01-23 10:01AM
08:00AM
Apr-25-23 02:30PM
Apr-19-23 01:07PM
Apr-14-23 08:30AM
Apr-11-23 11:15AM
Apr-07-23 08:30AM
Apr-04-23 04:05PM
Apr-03-23 08:30AM
Mar-30-23 08:30AM
Mar-24-23 08:30AM
Mar-13-23 02:51AM
Mar-09-23 10:42PM
(Thomson Reuters StreetEvents) -22.26%
08:45AM
07:30AM
Mar-02-23 08:30AM
Feb-23-23 04:05PM
05:34AM
(American City Business Journals)
Feb-21-23 06:30AM
Feb-01-23 04:05PM
Jan-03-23 04:05PM
Dec-22-22 08:45AM
Dec-02-22 04:05PM
Nov-22-22 04:05PM
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Butler John P. CEO and President Feb 29 '24 Sale 1.58 46,570 73,581 2,044,580 Mar 01 05:47 PM Dahan Michel SVP, Chief Operating Officer Feb 29 '24 Sale 1.58 8,661 13,684 706,932 Mar 01 05:49 PM Burke Steven Keith SVP, Chief Medical Officer Feb 29 '24 Sale 1.58 7,169 11,327 695,840 Mar 01 05:46 PM Hadas Nicole R. SVP, Chief Legal Officer Feb 29 '24 Sale 1.58 5,974 9,439 663,259 Mar 01 05:48 PM Butler John P. CEO and President Feb 27 '24 Sale 1.52 37,733 57,354 2,091,150 Feb 29 06:00 PM Dahan Michel SVP, Chief Operating Officer Feb 27 '24 Sale 1.52 10,744 16,331 715,593 Feb 29 06:02 PM Burke Steven Keith SVP, Chief Medical Officer Feb 27 '24 Sale 1.52 8,367 12,718 703,009 Feb 29 06:01 PM Hadas Nicole R. SVP, Chief Legal Officer Feb 27 '24 Sale 1.52 7,411 11,265 669,233 Feb 29 06:03 PM Butler John P. CEO and President Feb 01 '24 Sale 1.68 46,489 78,102 2,128,883 Feb 02 04:10 PM Burke Steven Keith SVP, Chief Medical Officer Feb 01 '24 Sale 1.68 24,311 40,842 711,376 Feb 02 04:10 PM Dahan Michel SVP, Chief Operating Officer May 25 '23 Sale 1.22 95,478 116,760 574,037 May 25 09:01 PM Hadas Nicole R. SVP, Chief Legal Officer May 25 '23 Sale 1.22 63,186 77,270 524,344 May 25 09:01 PM Burke Steven Keith SVP, Chief Medical Officer May 16 '23 Sale 1.07 63,567 67,890 530,487 May 18 06:20 PM Spellman David A SVP, CFO and Treasurer May 16 '23 Sale 1.07 63,567 67,890 446,483 May 18 06:19 PM
Index RUT
P/E -
EPS (ttm) -0.08
Insider Own 0.79%
Shs Outstand 48.38M
Perf Week 3.59%
Market Cap 2.31B
Forward P/E 97.92
EPS next Y 0.49
Insider Trans -39.65%
Shs Float 48.00M
Perf Month -5.39%
Income -3.18M
PEG -
EPS next Q -0.11
Inst Own 109.30%
Short Float 9.44%
Perf Quarter 11.22%
Sales 197.52M
P/S 11.68
EPS this Y 214.48%
Inst Trans -1.98%
Short Ratio 10.54
Perf Half Y 36.29%
Book/sh 4.72
P/B 10.10
EPS next Y 507.93%
ROA -1.02%
Short Interest 4.53M
Perf Year 48.52%
Cash/sh 2.63
P/C 18.13
EPS next 5Y -
ROE -1.52%
52W Range 30.18 - 53.05
Perf YTD 33.96%
Dividend Est. -
P/FCF 150.84
EPS past 5Y 19.85%
ROI -1.03%
52W High -10.08%
Beta 1.76
Dividend TTM -
Quick Ratio 4.21
Sales past 5Y 17.25%
Gross Margin 68.64%
52W Low 58.06%
ATR (14) 1.64
Dividend Ex-Date -
Current Ratio 4.49
EPS Y/Y TTM 80.74%
Oper. Margin -3.27%
RSI (14) 52.92
Volatility 3.16% 3.50%
Employees 314
Debt/Eq 0.39
Sales Y/Y TTM 20.17%
Profit Margin -1.61%
Recom 1.00
Target Price 53.90
Option/Short Yes / Yes
LT Debt/Eq 0.36
EPS Q/Q 113.62%
Payout -
Rel Volume 0.44
Prev Close 47.88
Sales Surprise 1.64%
EPS Surprise 49.68%
Sales Q/Q 23.35%
Earnings May 08 BMO
Avg Volume 430.07K
Price 47.70
SMA20 1.02%
SMA50 1.17%
SMA200 22.49%
Trades
Volume 132,810
Change -0.37%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-24 Upgrade
Truist
Hold → Buy
$39 → $51
Aug-08-23 Upgrade
BTIG Research
Neutral → Buy
$39
Nov-10-22 Downgrade
BTIG Research
Buy → Neutral
Nov-09-22 Downgrade
Truist
Buy → Hold
Oct-14-22 Resumed
Stephens
Overweight
$40
Jan-11-21 Downgrade
Oppenheimer
Outperform → Perform
Dec-18-20 Initiated
Stephens
Overweight
$31
Sep-17-20 Initiated
Truist
Buy
$24
Oct-09-19 Initiated
H.C. Wainwright
Buy
$19
Feb-28-19 Downgrade
Needham
Buy → Hold
Aug-08-18 Reiterated
Needham
Buy
$15 → $14
Jul-16-18 Upgrade
Ladenburg Thalmann
Neutral → Buy
Apr-04-18 Initiated
Leerink Partners
Outperform
$15
Mar-06-18 Reiterated
Needham
Buy
$5 → $15
Mar-06-18 Downgrade
Ladenburg Thalmann
Buy → Neutral
Mar-05-18 Reiterated
BTIG Research
Buy
$8 → $13
Jun-21-17 Initiated
BTIG Research
Buy
$6
Mar-13-17 Reiterated
Needham
Buy
$9 → $6
Dec-22-16 Initiated
Piper Jaffray
Overweight
$6
Nov-09-16 Reiterated
Needham
Buy
$12 → $9
Show Previous Ratings
Apr-24-24 08:30AM
Mar-29-24 07:01PM
Mar-28-24 01:48PM
(Investor's Business Daily)
Mar-15-24 07:00PM
Mar-01-24 09:30AM
11:37PM
Loading…
Feb-29-24 11:37PM
(Thomson Reuters StreetEvents)
09:05AM
08:32AM
07:55AM
Feb-27-24 08:30AM
Feb-22-24 12:00PM
Feb-18-24 03:00AM
Feb-15-24 10:00AM
08:50AM
08:30AM
08:30AM
Loading…
Feb-05-24 08:30AM
Jan-30-24 11:01PM
08:50AM
Jan-25-24 09:49AM
Jan-24-24 07:01PM
Jan-19-24 08:28PM
Jan-09-24 08:47AM
07:55AM
Jan-03-24 08:30AM
Dec-17-23 03:01AM
Dec-09-23 03:05AM
Dec-02-23 05:04AM
Nov-23-23 07:04AM
Nov-16-23 05:35PM
Nov-10-23 09:52PM
03:56PM
Loading…
Nov-09-23 03:56PM
Nov-08-23 03:30PM
07:55AM
Nov-07-23 08:30AM
Nov-01-23 10:01AM
Oct-25-23 08:30AM
Oct-24-23 01:22AM
Oct-23-23 05:59PM
Oct-16-23 10:23AM
Sep-28-23 08:30AM
Sep-20-23 04:30PM
Sep-06-23 08:30AM
Aug-10-23 01:48AM
Aug-02-23 09:05AM
07:55AM
Jul-23-23 11:44AM
Jul-20-23 08:30AM
Jul-10-23 09:30AM
Jun-21-23 08:00PM
May-10-23 09:05AM
07:55AM
May-02-23 09:00AM
Apr-26-23 08:00PM
08:30AM
Apr-24-23 02:06AM
Apr-17-23 03:03PM
Feb-28-23 08:30AM
Feb-23-23 09:45AM
07:55AM
Feb-09-23 08:00AM
Jan-31-23 07:19AM
Jan-11-23 10:24PM
Jan-10-23 07:55AM
Jan-04-23 08:34AM
Dec-30-22 01:42PM
(American City Business Journals)
05:26AM
Dec-29-22 01:46PM
01:45PM
Nov-11-22 06:09AM
Nov-10-22 09:00AM
Nov-09-22 09:05AM
07:55AM
Oct-26-22 08:30AM
Oct-10-22 11:50AM
Sep-22-22 08:30AM
Sep-06-22 08:30AM
Aug-09-22 09:55AM
Aug-04-22 04:30AM
Aug-03-22 09:05AM
07:55AM
07:30AM
Jul-21-22 04:05PM
Jul-20-22 08:30AM
Jul-08-22 08:30AM
Jun-30-22 10:50AM
May-04-22 08:30PM
09:05AM
07:55AM
Apr-20-22 08:30AM
Apr-09-22 08:07AM
Mar-15-22 08:30AM
Mar-01-22 08:30AM
Feb-24-22 06:30PM
04:45PM
09:15AM
07:55AM
Feb-17-22 03:02PM
Feb-10-22 09:00AM
Feb-02-22 04:05PM
Jan-25-22 09:38PM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Colangelo Dominick President and CEO Apr 30 '24 Option Exercise 11.79 25,445 299,977 220,752 May 01 04:05 PM Colangelo Dominick President and CEO Apr 18 '24 Option Exercise 3.02 17,500 52,850 212,807 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 18 '24 Sale 44.59 17,500 780,325 195,307 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 17 '24 Option Exercise 3.02 17,500 52,850 212,807 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 17 '24 Sale 46.47 17,500 813,225 195,307 Apr 19 04:05 PM Rubino Alan L Director Apr 09 '24 Option Exercise 4.12 3,000 12,360 20,594 Apr 11 04:05 PM ZERBE ROBERT L MD Director Mar 27 '24 Option Exercise 3.74 3,278 12,260 26,673 Mar 29 04:05 PM ZERBE ROBERT L MD Director Mar 27 '24 Sale 51.57 3,278 169,046 23,395 Mar 29 04:05 PM Colangelo Dominick President and CEO Mar 14 '24 Option Exercise 3.02 17,500 52,850 212,370 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 14 '24 Sale 44.02 17,500 770,350 194,870 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 13 '24 Option Exercise 3.02 17,500 52,850 212,370 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 13 '24 Sale 44.67 17,500 781,725 194,870 Mar 15 04:07 PM Halpin Michael Chief Operating Officer Mar 11 '24 Sale 44.71 7,874 352,047 949 Mar 13 04:05 PM Flynn Sean C. SVP, General Counsel Mar 08 '24 Sale 45.33 8,115 367,853 167 Mar 11 04:07 PM SIEGAL JONATHAN Principal Accounting Officer Mar 07 '24 Sale 45.00 1,634 73,530 1,400 Mar 11 04:08 PM ZERBE ROBERT L MD Director Feb 20 '24 Option Exercise 3.74 722 2,700 24,117 Feb 22 04:07 PM Hopper Jonathan Mark Chief Medical Officer Feb 20 '24 Option Exercise 0.00 7,075 0 58,695 Feb 22 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Feb 20 '24 Option Exercise 0.00 2,920 0 3,900 Feb 22 04:06 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 20 '24 Option Exercise 0.00 7,380 0 20,097 Feb 22 04:06 PM Colangelo Dominick President and CEO Feb 20 '24 Option Exercise 0.00 38,887 0 199,013 Feb 22 04:06 PM Flynn Sean C. SVP, General Counsel Feb 20 '24 Option Exercise 0.00 7,075 0 9,059 Feb 22 04:07 PM Halpin Michael Chief Operating Officer Feb 20 '24 Option Exercise 0.00 11,887 0 10,155 Feb 22 04:07 PM ZERBE ROBERT L MD Director Feb 20 '24 Sale 50.01 722 36,107 23,395 Feb 22 04:07 PM Colangelo Dominick President and CEO Feb 15 '24 Option Exercise 3.02 17,500 52,850 191,508 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 15 '24 Sale 48.85 17,500 854,875 174,008 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 14 '24 Option Exercise 3.02 17,500 52,850 191,508 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 14 '24 Sale 46.99 17,500 822,325 174,008 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 12 '24 Option Exercise 0.00 7,500 0 177,485 Feb 13 04:05 PM Halpin Michael Chief Operating Officer Feb 12 '24 Option Exercise 0.00 3,500 0 4,449 Feb 13 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 12 '24 Option Exercise 0.00 1,625 0 54,759 Feb 13 04:06 PM ZERBE ROBERT L MD Director Jan 29 '24 Sale 44.22 2,300 101,706 23,395 Jan 30 04:05 PM ZERBE ROBERT L MD Director Jan 25 '24 Sale 44.02 200 8,804 25,695 Jan 29 04:05 PM ZERBE ROBERT L MD Director Jan 22 '24 Option Exercise 4.12 3,000 12,360 28,895 Jan 24 04:05 PM ZERBE ROBERT L MD Director Jan 22 '24 Sale 41.85 8,000 334,775 25,895 Jan 24 04:05 PM Colangelo Dominick President and CEO Jan 18 '24 Option Exercise 3.02 16,726 50,513 186,711 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 18 '24 Sale 38.58 16,726 645,289 169,985 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 17 '24 Option Exercise 3.02 16,726 50,513 186,711 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 17 '24 Sale 37.97 16,726 635,086 169,985 Jan 19 04:06 PM ZERBE ROBERT L MD Director Jan 12 '24 Sale 38.09 2,200 83,798 30,895 Jan 16 04:05 PM Colangelo Dominick President and CEO Dec 14 '23 Option Exercise 3.57 12,000 42,840 181,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 14 '23 Sale 37.12 12,000 445,440 169,985 Dec 15 04:05 PM Wotton Paul K Director Dec 14 '23 Sale 37.31 5,000 186,550 26,802 Dec 15 04:07 PM Flynn Sean C. SVP, General Counsel Dec 14 '23 Sale 37.45 106 3,970 4,467 Dec 15 04:07 PM Colangelo Dominick President and CEO Dec 13 '23 Option Exercise 3.57 12,000 42,840 181,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 13 '23 Sale 34.03 12,000 408,360 169,985 Dec 15 04:05 PM Flynn Sean C. SVP, General Counsel Dec 13 '23 Sale 34.20 1,432 48,974 4,573 Dec 15 04:07 PM Colangelo Dominick President and CEO Dec 07 '23 Option Exercise 3.57 12,000 42,840 188,742 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 07 '23 Sale 33.84 12,000 406,080 176,742 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 06 '23 Option Exercise 3.57 12,397 44,257 189,139 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 06 '23 Sale 34.43 12,397 426,829 176,742 Dec 08 04:05 PM Halpin Michael Chief Operating Officer Nov 30 '23 Option Exercise 7.20 17,447 125,618 18,274 Dec 01 04:05 PM Halpin Michael Chief Operating Officer Nov 30 '23 Sale 35.41 17,447 617,798 827 Dec 01 04:05 PM Hopper Jonathan Mark Chief Medical Officer Nov 20 '23 Option Exercise 10.95 5,000 54,750 58,007 Nov 22 04:05 PM Hopper Jonathan Mark Chief Medical Officer Nov 20 '23 Sale 36.40 5,000 182,000 53,007 Nov 22 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Nov 15 '23 Sale 37.70 662 24,954 1,305 Nov 17 04:06 PM ZERBE ROBERT L MD Director Nov 15 '23 Sale 38.02 300 11,406 33,095 Nov 17 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Oct 02 '23 Option Exercise 0.00 938 0 2,134 Oct 04 04:05 PM ZERBE ROBERT L MD Director Jul 14 '23 Sale 38.84 1,000 38,840 33,395 Jul 17 04:05 PM ZERBE ROBERT L MD Director Jun 22 '23 Sale 36.00 3,000 108,000 34,395 Jun 26 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite